- Home
- TLSA vs CTMX Comparison
TLSA vs CTMX Comparison
Compare TLSA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- CTMX
- Stock Information
- Founded
- TLSA 2013
- CTMX 2008
- Country
- TLSA United Kingdom
- CTMX United States
- Employees
- TLSA N/A
- CTMX N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- CTMX Health Care
- Exchange
- TLSA Nasdaq
- CTMX Nasdaq
- Market Cap
- TLSA 187.0M
- CTMX 444.3M
- IPO Year
- TLSA 2000
- CTMX 2015
- Fundamental
- Price
- TLSA $1.48
- CTMX $2.39
- Analyst Decision
- TLSA
- CTMX Strong Buy
- Analyst Count
- TLSA 0
- CTMX 2
- Target Price
- TLSA N/A
- CTMX $5.00
- AVG Volume (30 Days)
- TLSA 242.1K
- CTMX 2.4M
- Earning Date
- TLSA 07-22-2025
- CTMX 08-07-2025
- Dividend Yield
- TLSA N/A
- CTMX N/A
- EPS Growth
- TLSA N/A
- CTMX 128.27
- EPS
- TLSA N/A
- CTMX 0.49
- Revenue
- TLSA N/A
- CTMX $147,557,000.00
- Revenue This Year
- TLSA N/A
- CTMX N/A
- Revenue Next Year
- TLSA N/A
- CTMX N/A
- P/E Ratio
- TLSA N/A
- CTMX $4.91
- Revenue Growth
- TLSA N/A
- CTMX 23.81
- 52 Week Low
- TLSA $0.63
- CTMX $0.40
- 52 Week High
- TLSA $1.91
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- TLSA 47.20
- CTMX 51.66
- Support Level
- TLSA $1.43
- CTMX $2.33
- Resistance Level
- TLSA $1.81
- CTMX $2.79
- Average True Range (ATR)
- TLSA 0.09
- CTMX 0.17
- MACD
- TLSA -0.02
- CTMX -0.01
- Stochastic Oscillator
- TLSA 13.16
- CTMX 42.03
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.